Description
Aprezo 30mg Tablet contains Apremilast, a selective phosphodiesterase-4 (PDE4) inhibitor. It works by reducing the production of inflammatory mediators, thereby controlling abnormal immune responses that cause psoriasis and psoriatic arthritis. This 30mg strength is the standard maintenance dose after completing the dose titration phase with Aprezo 10mg and Aprezo 20mg. It helps improve skin lesions, reduces joint inflammation, and enhances overall quality of life for patients with chronic autoimmune conditions.
Uses
-
Treatment of moderate to severe plaque psoriasis
-
Management of psoriatic arthritis (reducing pain, stiffness, and swelling)
-
Improves skin symptoms like scaling, itching, and redness
-
Enhances daily functioning by controlling joint-related symptoms
Dosage
-
Usual recommended dose: 30mg twice daily (after dose titration)
-
Taken orally with water, with or without food
-
Must be continued regularly for best results
-
Dosage adjustments may be required in patients with kidney impairment
-
Should be used only under medical supervision
Possible Side Effects
-
Diarrhea, nausea, or vomiting (commonly at treatment initiation)
-
Headache, dizziness, or fatigue
-
Weight loss or reduced appetite
-
Insomnia (trouble sleeping)
-
Rare but serious: mood changes, depression, or suicidal thoughts (patients must report these immediately)
About the Company
Glenmark Pharmaceuticals Ltd is a leading Indian multinational drug manufacturer with strong presence in dermatology, oncology, and respiratory therapies. Its Aprezo range is the first Apremilast brand launched in India, making advanced psoriasis treatment accessible at affordable prices compared to global brands.
Good Things About Aprezo 30mg Tablet
-
Maintenance dose for long-term disease management
-
Oral tablet form – convenient and non-invasive
-
Provides significant improvement in skin clearance and joint mobility
-
Helps maintain remission and reduces flare-ups
-
Backed by Glenmark’s trusted quality and affordability
Leave a Reply